Country for PR: United Kingdom
Contributor: PR Newswire Europe
Tuesday, June 20 2017 - 09:00
AsiaNet
New Medical Cannabis Joint Venture: LeafCann and iCAN: Israel-Cannabis Form iCAN: Australia
TEL AVIV, Israel and MELBOURNE, Australia, June 20, 2017 /PRNewswire-AsiaNet/ --

     - Agreement Paves Way for Significant Israel-Australia Medical Cannabis 
Collaboration

    iCAN: Israel-Cannabis (iCAN), a leading Israeli developer of medical 
cannabis formulations, clinical trials and cannabis testing, has formed a joint 
venture with LeafCann Research and Advisory, a leader in the development of 
cannabis medications, clinical research and education, based in Melbourne, 
Australia. The new venture, iCAN: Australia, will collaborate on a range of 
initiatives including medicinal cannabis research, education, acceleration, and 
innovation.

    This joint venture is a significant step in the collaborative efforts 
between Israel and Australia in this field, combining Israel's role as the 
world's medical cannabis R&D powerhouse with Australia's newly eased access 
regulations for patients in need.

    "We are thrilled to partner with LeafCann to form iCAN: Australia. Our 
collaboration will bring world-class cannabis products to the Australian market 
as well as accelerate our collaborative research and development of new 
products for a range of indications," said Saul Kaye, CEO of iCAN: 
Israel-Cannabis.

    The burgeoning global medical cannabis industry is estimated to reach $50 
billion by 2025.

    "This agreement paves the way for significant investment in clinical 
research to support the development of evidence based cannabis medicines for 
patients most in need. In addition iCAN: Australia will develop global clinical 
education initiatives to bridge the gap between public demand and practitioner 
education. We are also excited to be part of iCAN's global acceleration program 
to develop a professional, ethical and sustainable medicinal cannabis sector 
worldwide," said LeafCann Group CEO, Dr Jaroslav Boublik B.Sc. (Hons) Ph.D. 
(Med), MRACI, C.Chem. AACNEM, MICRS.

    LeafCann's practitioner education program will be incorporated into iCAN's 
product offerings and distributed via iCAN's global reach. In addition, iCAN: 
Australia will take a significant interest in CannaTech Australia, the 
country's first major Medical Cannabis Summit modeled after the highly 
successful CannaTech Israel Summits. The first CannaTech Australia conference 
will take place in Sydney in 2018.

    About iCAN: Israel-Cannabis

    iCAN [http://www.israel-cannabis.com ]: Israel-Cannabis is a leading 
Israeli developer of cannabis based formulations, clinical trials and cannabis 
testing. iCAN is committed to accelerate Israel's CannaTechnology industry, 
capitalizing on Israeli innovation and a  leading cannabis regulatory 
environment to bring premier products to market. iCAN is powered by CannaTech, 
the premier international cannabis summit held annually in Tel Aviv and for the 
first time outside of Israel on October 25th and 26th in London, England.

    About LeafCann LeafCann [http://www.leafcann.com.au ] Research and Advisory 
is a wholly owned subsidiary of LeafCann Group Pty Ltd. LeafCann Research and 
Advisory is a leading Australian developer of clinical research, product 
development, education and Industry advice to a range of Australian and 
international partners. LeafCann Group has positioned itself as Australia's 
preeminent Medicinal Cannabis think tank. With strong strategic partnerships, a 
diverse team and significant investment in medicinal cannabis production in 
Australia, LeafCann Group is well positioned as a global leader.



    Contact:     
    Kam Global Strategies,     
    laura@kamgs.com ,     
    +972-54-806-8613 

    Source: iCAN: Israel-Cannabis and LeafCann Research and Advisory